Program
sildenafil
Also written as “Sildenafil”, “Sildenafil citrate” and “sildenafil citrate”.
Its studies are mostly in Erectile Dysfunction · Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Sexual Dysfunctions, Psychological · Persistent Fetal Circulation Syndrome, led by 10 companies.
Drug pageSildenafil: every studyMany companies study it; this page follows only the 60 they lead. All 330 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Viatrisits history only | 470 open or running | phase 4since Aug 26, 2005 | Aug 26, 2005 | none ahead |
| Strategic Science & Technologiesits history only | 40 open or running | phase 2since Mar 9, 2015 | Oct 29, 2013 | none ahead |
| Hanmi Pharmaceuticalits history only | 20 open or running | phase 3since Jul 30, 2013 | Jan 18, 2012 | none ahead |
| Daré Bioscienceits history only | 10 open or running | phase 1since Mar 1, 2023 | Mar 1, 2023 | none ahead |
| Emotional Brain NY | 10 open or running | phase 2since Aug 17, 2011 | Aug 17, 2011 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Mar 11, 2012 | Mar 11, 2012 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since Oct 28, 2016 | Oct 28, 2016 | none ahead |
| Laboratório Teuto Brasileiro S/Aits history only | 10 open or running | phase 3since Mar 15, 2011 | Mar 15, 2011 | none ahead |
| N4 Pharma UKits history only | 10 open or running | phase 1since Apr 12, 2018 | Apr 12, 2018 | none ahead |
| Pharmtechnologyits history only | 10 open or running | phase 1since May 6, 2021 | May 6, 2021 | none ahead |
Also a collaborator on its studies: Pfizer, BDD Pharma and ICOS.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Emotional Brain NY only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2011First study: phase 2 study in Sexual Dysfunctions, PsychologicalFirst studyNCT01432665 · 196 enrolled · United States
TargetBeta
“Phosphodiesterase 5A inhibitor”ChEMBL 37, by rule
Other programs on PDE5A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tadalafilrule | Eli Lilly | phase 4 | 73 |
Studies
The one study Emotional Brain NY leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01432665Sexual Dysfunctions, Psychological · United States | 2 | Completed | May 2013 | 196 |
How it is read
Names in the registry
- “Sildenafil”, 27 entries
- “sildenafil”, 18 entries
- “Sildenafil citrate”, 14 entries
- “sildenafil citrate”, 10 entries
- “Sildenafil Citrate”, 4 entries
Conditions, from the studies’ own filings
- Erectile Dysfunction, 33 studies
- Pulmonary Arterial Hypertension, 11 studies
- Hypertension, Pulmonary, 6 studies
- Sexual Dysfunctions, Psychological, 3 studies
- Persistent Fetal Circulation Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.